Current status and future promise of pharmacotherapeutic strategies for Alzheimer's disease

Journal of the American Medical Directors Association

Volumn 7, Issue 3 SUPPL., 2006, Pages

  Standridge, John B ^a  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Future treatment; Pharmacotherapy

Indexed keywords

ACETYLCHOLINESTERASE; ALPHA TOCOPHEROL; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID PRECURSOR PROTEIN; ASCORBIC ACID; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE; DONEPEZIL; GALANTAMINE; GLYCOPROTEIN P; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; INDOMETACIN; MEMANTINE; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; RIVASTIGMINE; SULINDAC; TAXANE DERIVATIVE; TX 67; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BLOOD BRAIN BARRIER; CELL CULTURE; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG RESPONSE; FUNCTIONAL ASSESSMENT; HUMAN; IN VITRO STUDY; MEDICAL RESEARCH; MEDLINE; MENINGOENCEPHALITIS; NEUROPROTECTION; NONHUMAN; REVIEW; SIDE EFFECT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW;

EID: 33144460377     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2005.12.015     Document Type: Article

References (56)

1. L.E. Hebert P.A. Scherr J.L. Bienias et al. Alzheimer disease in the US population Prevalence estimates using the 2000 census Arch Neurol 60 2003 1119-1122
2. R. Brookmeyer S. Gray C. Kawas Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset Am J Public Health 88 1998 1337-1342
3. J.L. Cummings G. Cole Alzheimer disease JAMA 287 2002 2335-2338
4. R. Schulz A.B. Mendelsohn W.E. Haley Resources for Enhancing Alzheimer's Caregiver Health (REACH) Investigators End-of-life care and the effects of bereavement on family caregivers of persons with dementia N Engl J Med 349 2003 1936-1942
5. Author's guide. American Academy of Family Physicians Web site. Available at http://www.aafp.org/x17444.xml. Accessed October 24, 2004.
6. S. Weggen J.L. Eriksen P. Das A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity Nature 414 2001 212-216
7. Y. Takahashi I. Hayashi Y. Tominari et al. Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation J Biol Chem 278 2003 18664-18670
8. H. Naiki K. Hasegawa I. Yamaguchi et al. Apolipoprotein E and antioxidants have different mechanisms of inhibiting Alzheimer's beta-amyloid fibril formation in vitro Biochemistry 37 1998 17882-17889
9. P.P. Zandi J.C. Anthony A.S. Khachaturian Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: The Cache County Study Arch Neurol 61 2004 82-88
10. M. Sano C. Ernesto R.G. Thomas A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study N Engl J Med 336 1997 1216-1222
11. M. Michikawa The role of cholesterol in pathogenesis of Alzheimer's disease: Dual metabolic interaction between amyloid beta-protein and cholesterol Mol Neurobiol 27 2003 1-12
12. R.W. Haley J.M. Dietschy Is there a connection between the concentration of cholesterol circulating in plasma and the rate of neuritic plaque formation in Alzheimer disease? Arch Neurol 57 2000 1410-1412
13. G.L. Vega M.F. Weiner A.M. Lipton Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease Arch Neurol 60 2003 510-515
14. M. Burns K. Duff Cholesterol in Alzheimer's disease and tauopathy Ann N Y Acad Sci 977 2002 367-375
15. E. Arias E. Ales N.H. Gabilan et al. Galantamine prevents apoptosis induced by beta-amyloid and thapsigargin: Involvement of nicotinic acetylcholine receptors Neuropharmacology 46 2004 103-114
16. Y. Takada A. Yonezawa T. Kume et al. Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons J Pharmacol Exp Ther 306 2003 772-777
17. M.M. Mesulam C. Geula Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia Ann Neurol 36 1994 722-727
18. T. Rees P.I. Hammond H. Soreq et al. Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex Neurobiol Aging 24 2003 777-787
19. W. Hu N.W. Gray S. Brimijoin Amyloid-beta increases acetylcholinesterase expression in neuroblastoma cells by reducing enzyme degradation J Neurochem 86 2003 470-478
20. T.M. Rees S. Brimijoin The role of acetylcholinesterase in the pathogenesis of Alzheimer's disease Drugs Today (Barc) 39 2003 75-83
21. N.H. Greig D.K. Lahiri K. Sambamurti Butyrylcholinesterase: An important new target in Alzheimer's disease therapy Int Psychogeriatr 14 Suppl 1 2002 77-91
22. A.L. Guillozet J.F. Smiley D.C. Mash M.M. Mesulam Butyrylcholinesterase in the life cycle of amyloid plaques Ann Neurol 42 1997 909-918
23. N.C. Inestrosa A. Alvarez C.A. Perez et al. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils Possible role of the peripheral site of the enzyme Neuron 16 1996 881-891
24. L. Piazzi A. Rampa A. Bisi et al. 3-(4- Benzyl(methyl)amino]methyl]pheny l)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation A dual function lead for Alzheimer's disease therapy J Med Chem 46 2003 2279-2282
25. H. Ogura T. Kosasa Y. Kuriya Y. Yamanishi Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro Methods Find Exp Clin Pharmacol 22 2000 609-613
26. M. Samochocki A. Hoffle A. Fehrenbacher et al. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors J Pharmacol Exp Ther 305 2003 1024-1036
27. W. Danysz C.G. Parsons H.J. Möbius Neuroprotective and symptomatic action of memantine relevant for Alzheimer's disease: A unified glutamatergic hypothesis on the mechanism of action Neurotoxicity Res 2 2000 85-98
28. P.N. Tariot M.R. Farlow G.T. Grossberg et al. Memantine Study Group Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil JAMA 291 2004 317-324
29. J.B. Standridge Pharmacotherapeutic approaches to the treatment of Alzheimer's disease Clin Ther 26 2004 615-630
30. N.H. Trinh J. Hoblyn S. Mohanty K. Yaffe Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: A meta-analysis JAMA 289 2003 210-216
31. C. Holmes D. Wilkinson C. Dean The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease Neurology 63 2004 214-219
32. K.L. Lanctot N. Herrmann K.K. Yau Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: A meta-analysis CMAJ 169 2003 557-564
33. D.S. Geldmacher G. Provenzano T. McRae Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease J Am Geriatr Soc 51 2003 937-944
34. AD2000 Collaborative Group Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): Randomized double-blind trial Lancet 363 2004 2105-2115
35. J.L. Cummings Use of cholinesterase inhibitors in clinical practice: Evidence-based recommendations Am J Geriatr Psychiatry 11 2003 131-145
36. B. Reisberg R. Doody A. Stoffler et al. Memantine Study Group Memantine in moderate-to-severe Alzheimer's disease N Engl J Med 348 2003 1333-1341
37. B. Winblad N. Poritis Memantine in severe dementia Results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine) Int J Geriatr Psychiatry 14 1999 135-146
38. M.L. Michaelis Drugs targeting Alzheimer's disease: Some things old and some things new J Pharmacol Exp Ther 304 2003 897-904
39. L.M. Kopcho J. Ma J. Marcinkeviciene Comparative studies of active site-ligand interactions among various recombinant constructs of human beta-amyloid precursor protein cleaving enzyme Arch Biochem Biophys 410 2003 307-316
40. M. Citron Emerging Alzheimer's disease therapies: Inhibition of beta-secretase Neurobiol Aging 23 2002 1017-1022
41. D. Beher M.S. Shearman Gamma-secretase inhibition Biochem Soc Trans 30 2002 534-537
42. B. De Strooper Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex Neuron 38 2003 9-12
43. B. Permanne C. Adessi S. Fraga Are beta-sheet breaker peptides dissolving the therapeutic problem of Alzheimer's disease? J Neural Transm Suppl 62 2002 293-301
44. B. Permanne C. Adessi G.P. Saborio et al. Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a beta-sheet breaker peptide FASEB J 16 2002 860-862
45. C. Adessi M.J. Frossard C. Boissard et al. Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease J Biol Chem 278 2003 13905-13911
46. P. Talaga L. Quere The plasma membrane: A target and hurdle for the development of anti-Abeta drugs? Curr Drug Target CNS Neurol Disord 1 2002 567-574
47. B.I. Giasson V.M. Lee J.Q. Trojanowski Interactions of amyloidogenic proteins Neuromolecular Med 4 2003 49-58
48. M. Windisch B. Hutter-Paier E. Schreiner Current drugs and future hopes in the treatment of Alzheimer's disease J Neural Transm Suppl 62 2002 149-164
49. E. Giacobini Cholinesterases: New roles in brain function and in Alzheimer's disease Neurochem Res 28 2003 515-522
50. M.L. Michaelis R.T. Dobrowsky G. Li Tau neurofibrillary pathology and microtubule stability J Mol Neurosci 19 2002 289-293
51. A. Rice M.L. Michaelis G. Georg Overcoming the blood-brain barrier to taxane delivery for neurodegenerative diseases and brain tumors J Mol Neurosci 20 2003 339-343
52. C. Janus Vaccines for Alzheimer's disease How close are we? CNS Drugs 17 2003 457-474
53. C.A. Lemere A. Beierschmitt M. Iglesias Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet Am J Pathol 165 2004 283-297
54. N. Sergeant S. Bombois A. Ghestem Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach J Neurochem 85 2003 1581-1591
55. N.B. Chauhan G.J. Siegel Reversal of amyloid beta toxicity in Alzheimer's disease model Tg2576 by intraventricular antiamyloid beta antibody J Neurosci Res 69 2002 10-23
56. N.B. Chauhan G.J. Siegel Intracerebroventricular passive immunization with anti-Abeta antibody in Tg2576 J Neurosci Res 74 2003 142-147